Other Issues:
previous
|
next
|
latest
|
archive
Volume 7(Suppl 7); 2005
Introduction
Recent Developments in the Metabolic Management of BPH
Michael K Brawer
Rev Urol.
2005;
7
(Suppl 7)
: S1–S2.
PMCID:
PMC1477624
|
Full Text
|
PDF–14K
|
Metabolic Management of BPH
Pathophysiology of Lower Urinary Tract Symptoms in the Aging Male Population
Herbert Lepor
Rev Urol.
2005;
7
(Suppl 7)
: S3–S11.
PMCID:
PMC1477625
|
Abstract
|
Full Text
|
PDF–60K
|
The Development of Lonidamine for Benign Prostatic Hyperplasia and Other Indications
Claus G Roehrborn
Rev Urol.
2005;
7
(Suppl 7)
: S12–S20.
PMCID:
PMC1477628
|
Abstract
|
Full Text
|
PDF–57K
|
Lonidamine: Basic Science and Rationale for Treatment of Prostatic Proliferative Disorders
Michael K Brawer
Rev Urol.
2005;
7
(Suppl 7)
: S21–S26.
PMCID:
PMC1477623
|
Abstract
|
Full Text
|
PDF–45K
|
Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH
Pasquale Ditonno, Michele Battaglia, Oscar Selvaggio, Lucio Garofalo, Vito Lorusso, and Francesco Paolo Selvaggi
Rev Urol.
2005;
7
(Suppl 7)
: S27–S33.
PMCID:
PMC1477627
|
Abstract
|
Full Text
|
PDF–50K
|
Factors in Predicting Failure with Medical Therapy for BPH
Steven A Kaplan
Rev Urol.
2005;
7
(Suppl 7)
: S34–S39.
PMCID:
PMC1477626
|
Abstract
|
Full Text
|
PDF–38K
|
Other Issues:
previous
|
next
|
latest
|
archive
